Ovarian Cancer Action
8-12 Camden High Street
London NW1 0JH UK

Tel: +44 (0)20 7380 1730
Fax: +44 (0)20 7380 1748

www.ovarian.org.uk

Forum Venue: The Westin Diplomat Resort & Spa - Golf location
Hallandale, Florida, USA

Forum Dates: 15th – 19th January 2011

Board of Directors: Allyson J Kaye (Chair)
Daniel B Harris
John E Harris CBE
Martin D Paisner CBE
Emma J Scott
Lord Turnberg

Chief Executive: Peter Reynolds

Honorary Treasurer: Nicholas S Kaye FCA

Programme Committee: Professor Frances Balkwill (Chair)
Professor Alan Ashworth
Professor Robert Bast
Professor Andrew Berchuck
Professor Jonathan Berek
Professor Michael Birrer
Professor David Bowtell
Dr James Brenton
Dr George Coukos
Professor Hani Gabra
Professor Stan Kaye
Dr Elise Kohn
Professor Jonathan Ledermann
Professor Iain McNeish
Professor Gordon Mills
Allyson J Kaye

Review Editors: Dr Jermaine Coward
Dr Sebastian Vaughan

Forum Organiser: Colette Murphy, TOUCH Associates Ltd
Welcome to the Helene Harris Memorial Trust 12th International Forum on Ovarian Cancer, this year in Hallandale, Florida. Once again we are extremely proud to be able to bring together many of the world’s leading ovarian cancer scientists and clinicians to discuss and debate new directions in research and new collaborations to drive progress.

Everyone involved in the meeting will be conscious that progress in improving ovarian cancer survival rates has been frustratingly slow since the inception of the HHMT forums in 1986. Nonetheless, our understanding of how ovarian cancer develops and the information on the disease grows steadily and there has never been a time when there was cause for such optimism that we are making progress towards substantial improvements in survival rates.

Three years have passed since the last HHMT meeting. Over that time Ovarian Cancer Action has been very busy! We have made substantial progress in establishing the UK’s first centre dedicated to ovarian cancer research. Under the Directorship of Professor Hani Gabra, the Ovarian Cancer Action Research Centre is a collaboration between Imperial Hammersmith Hospital and the Royal Marsden Hospital in London.

Ovarian Cancer Action remains committed to involving all those affected by the disease to inform everything we do. Our supporters visit our Research Centre to learn about the work they have helped to make possible: they contribute to the development of our information materials; they tell their stories in the media to raise awareness of the disease and its symptoms; and they lobby Government to ensure policy makers are aware of, and act upon, their priorities and concerns. We hope that we will be able to maintain that philosophy over the next few days and focus on how we can best achieve progress that will make a clear difference to patients’ outcomes and experience of the disease.

We are grateful to all the delegates for making time to attend this invitation only meeting. My thanks go to Professor Fran Balkwill for chairing the Programme Committee, to Professor Andy Berchuck for chairing the Travelling Fellowship Judging Committee and to all the committee members for helping to put together a very exciting programme.

The HHMT Forums work best when attendees feel able to share and debate results openly, so please don’t hold back. We hope you find this meeting thought provoking and rewarding.

With best wishes

Allyson Kaye
Chair, Board of Directors
Welcome message from Frances Balkwill

It is a pleasure and privilege to welcome to Florida all participants of the Helene Harris Memorial Trust 12th International Forum on Ovarian Cancer.

By gathering together international experts in basic, translational and clinical research over the last twenty four years, the meetings of the Helene Harris Memorial Trust have made a tremendous contribution to progress in the field of ovarian cancer.

I would like to thank all members of the Programme Committee for their invaluable advice in developing the scientific programme and all members of the Fellowship Judging Panel for their dedication in evaluating the abstracts for the Fellowship prizes. In addition I wish to say a very special thank you to the Harris family, without whose sponsorship these gatherings would not be possible, and to Allyson Kaye and Colette Murphy for all they have done in organising this meeting. It is an exciting and fast-moving time for ovarian cancer research and this meeting reflects that in a way that will inform, stimulate and challenge.

Professor Frances Balkwill  
Barts and the London School of Medicine and Dentistry  
Chair, HHMT Programme Committee

A Message from Dr Tony Falconer

It is my great pleasure to endorse the Helene Harris Memorial Trust 12th International Forum on Ovarian Cancer, to be held in Hallandale, Florida in January 2011. This Forum provides a unique opportunity to bring together many of the world’s leading scientists and clinicians with an interest in the prevention and management of ovarian cancer. Meetings like this provide an opportunity to make real strides in treatment and research. Ovarian cancer is about prevention as well as management and there are a number of exciting developments in this area. I hope that the fruitful association between the Royal College of Obstetricians and Gynaecologists and Ovarian Cancer Action continues and this is also an opportunity for me to pay tribute to the ongoing work of the charity in supporting research and public education.

My good wishes for a successful meeting.

Dr Tony Falconer  
President, Royal College of Obstetricians and Gynaecologists
As part of our work to encourage the development of the next generation of ovarian cancer researchers, Ovarian Cancer Action offers six Travelling Fellowships. The key objective of this aspect of the programme is to inspire talented young scientists and clinicians to develop their careers in the field of ovarian cancer.

This year we were encouraged by both the overall quality and number of abstracts received, which exceeded 50. From a competitive field, the best six were selected by our panel of distinguished judges, Professor Andrew Berchuck (Chair), Professor James Brenton, Professor Christopher Crum, Dr Ernst Lengyel and Dr Douglas Levine.

The Travelling Fellows will present their work during the afternoon of the first day of the Forum, Sunday 16th January. A prize will be awarded at the Farewell Dinner for the best contribution.

Our thanks go to all those who participated in, adjudicated and organised these competitive Fellowships.

Sponsors

We would like to express our appreciation to the following for their support:

Morphotek
www.morphotek.com

Roche
www.rocheuk.com
Since joining Ovarian Cancer Action in 2008, it has been a privilege to work with so many inspirational scientists, clinicians, survivors and supporters, all of whom are playing such a vital role in improving the outlook for women with ovarian cancer.

I have been hugely impressed by the longstanding role played by the HHMT International Forums in encouraging discussion and debate on latest progress and future directions in ovarian cancer research. I would like to add my thanks to Professor Fran Balkwill for her invaluable support and advice on the organisation of this meeting, to Professor Andrew Berchuck for advising in relation to the Travelling Fellowships programme, and to all the committee members.

Since the last HHMT Forum in 2007, Ovarian Cancer Action has made substantial progress towards its goal of improving ovarian cancer survival rates:

**Funding research**
Thanks to our growing network of donors, the charity has been able to double its investment in the Ovarian Cancer Action Research Centre, based at Imperial Hammersmith Hospital, the Institute of Cancer Research and the Royal Marsden Hospital. The Research Centre is led by its Director Professor Hani Gabra, alongside Professors Bob Brown, Martin Gore, Stan Kaye and Henning Walczak. In 2009 the Centre moved to new expanded laboratories at the Hammersmith Hospital and now houses over 40 scientists.

**Raising awareness**
Addressing the issue of patient and system delay in diagnosing ovarian cancer is a key priority. This is undoubtedly a challenging area for healthcare professionals, but recent years have seen encouraging progress in reaching consensus on the potential signs and symptoms of the disease. The charity has been very active in disseminating this new information in the UK, through initiatives such as our "Remember the symptoms campaign, which has received widespread coverage in the national media, and by working closely with bodies such as the Royal College of GPs and Royal College of Nursing.

**Giving a voice**
We are determined to ensure that women’s voices are heard, to create better public awareness of ovarian cancer and to influence public health policy. Last year we launched a new supporter initiative, Ovarian Cancer Voices, which provides a platform for our supporters who wish to contribute to this work.

None of the progress the charity has made would be possible without our supporters and I wish to pay tribute to them for everything that they do, as well as thanking you for all your efforts in improving the outlook for women affected by ovarian cancer.

Peter Reynolds
Chief Executive
Ovarian Cancer Action
Saturday 15th January

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00pm</td>
<td>Welcome Reception</td>
<td>Fountain Terrace</td>
</tr>
<tr>
<td></td>
<td>Allyson Kaye, Chair, Board of Directors</td>
<td></td>
</tr>
<tr>
<td>10:00pm</td>
<td>Close</td>
<td></td>
</tr>
</tbody>
</table>

Sunday 16th January (morning)

Prevention and Early Diagnosis

**MORNING SESSION**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30am</td>
<td>Welcome</td>
<td>Ballroom Salon A &amp; B</td>
</tr>
<tr>
<td></td>
<td>Frances Balkwill</td>
<td>Barts and The London School of Medicine and Dentistry, UK</td>
</tr>
<tr>
<td>8:35am</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jonathan Berek</td>
<td>Stanford University, USA</td>
</tr>
<tr>
<td>8:40am</td>
<td>Early detection of ovarian cancer: The MDACC ovarian SPORE trial and development of strategies to detect pre clinical disease</td>
<td>UTMD Anderson Cancer Center, USA</td>
</tr>
<tr>
<td>9:15am</td>
<td>Serial CA125 can detect ovarian cancer in the absence of ultrasound abnormalities</td>
<td>UCL Elizabeth Garrett Institute of Women's Health, UK</td>
</tr>
<tr>
<td>9:50am</td>
<td>Role of common variants in ovarian cancer susceptibility: development of an International Ovarian Cancer Association Consortium</td>
<td>Duke University Medical Center, USA</td>
</tr>
<tr>
<td>10:25am</td>
<td>Break</td>
<td>Ballroom Foyer</td>
</tr>
<tr>
<td>10:55am</td>
<td>Identification and characterisation of common low penetrance susceptibility alleles for ovarian cancer from a genome wide association study</td>
<td>UCL Elizabeth Garrett Institute of Women's Health, UK</td>
</tr>
<tr>
<td>11:30am</td>
<td>Novel diagnostic tools for ovarian cancer early detection</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Amelie Lutz</td>
<td>Stanford University, USA</td>
</tr>
<tr>
<td>12:05pm</td>
<td>Review Session</td>
<td></td>
</tr>
<tr>
<td>12:50pm</td>
<td>Lunch</td>
<td>Royal Palm</td>
</tr>
</tbody>
</table>

**NOTE:** Each presentation will be a maximum of 25 minutes in duration with a further 10 minutes for questions and discussion.
<table>
<thead>
<tr>
<th>TIME</th>
<th>SESSION</th>
<th>SPEAKER</th>
<th>INSTITUTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00pm</td>
<td><strong>Introduction</strong></td>
<td>Andrew Berchuck</td>
<td>Duke University Medical Center, USA</td>
</tr>
<tr>
<td>2:05pm</td>
<td><strong>Characterization of genomic alterations in early-stage ovarian cancer</strong></td>
<td>Jeremy Chien</td>
<td>The Mayo Clinic, USA</td>
</tr>
<tr>
<td>2:30pm</td>
<td><strong>Progress in modeling fallopian tube epithelial and serous tumorigenesis</strong></td>
<td>Ronny Drapkin</td>
<td>Dana-Farber Cancer Institute, USA</td>
</tr>
<tr>
<td>2:55pm</td>
<td><strong>CCNE1 de-regulation in ovarian cancer via 19q12 amplification is critical for viability, clonogenic survival following cisplatin treatment, and is highly correlated with 20q11 amplification of the centromeric protein, TPX2</strong></td>
<td>Dariush Etemadmoghadam</td>
<td>Peter MacCallum Cancer Centre, Australia</td>
</tr>
<tr>
<td>3:00pm</td>
<td><strong>Break</strong></td>
<td></td>
<td>Ballroom Foyer</td>
</tr>
<tr>
<td>3:50pm</td>
<td><strong>Population-based testing for high-penetration autosomal dominant gene mutations: a proof of principle RCT in the Ashkenazi Jewish population</strong></td>
<td>Ranjit Manchanda</td>
<td>UCL Elizabeth Garrett Institute for Women’s Health, UK</td>
</tr>
<tr>
<td>4:15pm</td>
<td><strong>Ovarian clear cell carcinomas: molecular heterogeneity, therapeutic targets and prognostic subgroups – a microarray-based comparative genomic hybridisation analysis</strong></td>
<td>David Tan</td>
<td>The Royal Marsden Hospital NHS Foundation Trust, UK</td>
</tr>
<tr>
<td>4:40pm</td>
<td><strong>ARID1A gene mutations in endometriosis associated ovarian carcinomas</strong></td>
<td>Kimberly Wiegand</td>
<td>British Columbia Cancer Agency, Canada</td>
</tr>
<tr>
<td>5:05pm</td>
<td><strong>Close</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30pm</td>
<td><strong>Bus to dinner</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:45pm</td>
<td><strong>Dinner</strong></td>
<td></td>
<td>Rivals Bar</td>
</tr>
</tbody>
</table>

**NOTE:** Travelling Fellowship talks will last a maximum of 20 minutes, with 5 minutes for questions.
### MORNING SESSION

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30am</td>
<td>Introduction</td>
<td>Elise Kohn</td>
<td>National Cancer Institute, USA</td>
</tr>
<tr>
<td>8:35am</td>
<td>An iconoclast’s view towards improving the outcome of women with ovarian cancer</td>
<td>Michael Seiden</td>
<td>Fox Chase Cancer Center, USA</td>
</tr>
<tr>
<td>9:10am</td>
<td>Targeted therapies in ovarian cancer</td>
<td>Amit Oza</td>
<td>Princess Margaret Hospital, Canada</td>
</tr>
<tr>
<td>9:45am</td>
<td>Chemotherapy for platinum resistant ovarian cancer – does the punishment fit the benefit?</td>
<td>Michael Friedlander</td>
<td>Prince of Wales Hospital, Australia</td>
</tr>
</tbody>
</table>

#### Lunch

- **12:15pm** **Lunch**

#### Break

- **10:20am** **Break**
  - **10:50am** **The BAD pathway and ovarian cancer chemo-response and clinical outcome**
    - Johnathan Lancaster
    - H. Lee Moffitt Cancer Center & Research Institute, USA

#### Discussion

- **12:00pm** **Discussion**

### AFTERNOON SESSION

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:25pm</td>
<td>Introduction</td>
<td>Hani Gabra</td>
<td>Imperial College London, UK</td>
</tr>
<tr>
<td>1:30pm</td>
<td>Using synthetic lethality approaches to design novel therapeutic approaches to cancer treatment</td>
<td>Christopher Lord</td>
<td>Institute of Cancer Research, UK</td>
</tr>
<tr>
<td>2:05pm</td>
<td>Clinical perspectives on PARP inhibitor therapy for ovarian cancer</td>
<td>Stan Kaye</td>
<td>Royal Marsden Hospital, UK</td>
</tr>
<tr>
<td>2:40pm</td>
<td>Targeting PARP inhibitors: developing biomarkers based on homologous recombination</td>
<td>Richard Edmondson</td>
<td>Queen Elizabeth Hospital, UK</td>
</tr>
</tbody>
</table>

#### Break

- **3:15pm** **Break**

#### Review Session

- **4:20pm** **Review Session**

#### Close

- **5:20pm** **Close**

#### Buffet Dinner

- **7:00pm** **Buffet Dinner**

---

**NOTE:** Each presentation will be a maximum of 25 minutes in duration with a further 10 minutes for questions and discussion.
## Tuesday 18th January

### Classification of Ovarian Cancer, Omics and Implications for Personalised Treatment

<table>
<thead>
<tr>
<th>MORNING SESSION</th>
<th>Ballroom Salon A &amp; B</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chair:</strong></td>
<td>Jonathan Ledermann</td>
</tr>
<tr>
<td><strong>University College London, UK</strong></td>
<td></td>
</tr>
<tr>
<td><strong>8:30am</strong></td>
<td><strong>Introduction</strong></td>
</tr>
<tr>
<td>Jonathan Ledermann</td>
<td>University College London, UK</td>
</tr>
<tr>
<td><strong>8:35am</strong></td>
<td><strong>The origin and pathogenesis of ovarian cancer. Shifting the paradigm</strong></td>
</tr>
<tr>
<td>Robert Kurman</td>
<td>John Hopkins Hospital, USA</td>
</tr>
<tr>
<td><strong>9:10am</strong></td>
<td><strong>Precursors to pelvic serous cancer in the fallopian tube: opportunities for early detection and risk assessment</strong></td>
</tr>
<tr>
<td>Christopher Crum</td>
<td>Brigham &amp; Women’s Hospital, USA</td>
</tr>
<tr>
<td><strong>9:45am</strong></td>
<td><strong>Findings from The Cancer Genome Atlas Pilot Project in ovarian cancer</strong></td>
</tr>
<tr>
<td>Douglas Levine</td>
<td>Memorial Sloan-Kettering Cancer Centre, USA</td>
</tr>
<tr>
<td><strong>10:20am</strong></td>
<td><strong>Break</strong></td>
</tr>
<tr>
<td><strong>Ballroom Foyer</strong></td>
<td></td>
</tr>
<tr>
<td><strong>10:50am</strong></td>
<td><strong>Ovarian cancer subtypes at base pair resolution</strong></td>
</tr>
<tr>
<td>David Huntsman</td>
<td>British Columbia Cancer Agency, Canada</td>
</tr>
<tr>
<td><strong>11:25am</strong></td>
<td><strong>The post Cancer Genome Atlas era: where do we go?</strong></td>
</tr>
<tr>
<td>Michael Birrer</td>
<td>Massachusetts General Hospital, USA</td>
</tr>
<tr>
<td><strong>12:00pm</strong></td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td><strong>12:15pm</strong></td>
<td><strong>Lunch</strong></td>
</tr>
<tr>
<td><strong>Royal Palm</strong></td>
<td></td>
</tr>
<tr>
<td><strong>1:15pm</strong></td>
<td><strong>Free time</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>AFTERNOON SESSION</th>
<th>Ballroom Salon A &amp; B</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chair:</strong></td>
<td>James Brenton</td>
</tr>
<tr>
<td><strong>Cancer Research UK Cambridge Research Institute, UK</strong></td>
<td></td>
</tr>
<tr>
<td><strong>5:00pm</strong></td>
<td><strong>Introduction</strong></td>
</tr>
<tr>
<td>James Brenton</td>
<td>Cancer Research UK Cambridge Research Institute, UK</td>
</tr>
<tr>
<td><strong>5:05pm</strong></td>
<td><strong>Molecular subtypes of ovarian cancer: insights into the drivers of high-grade ovarian serous and clear cell tumours</strong></td>
</tr>
<tr>
<td>David Bowtell</td>
<td>Peter MacCullum Cancer Centre, Australia</td>
</tr>
<tr>
<td><strong>5:40pm</strong></td>
<td><strong>Systems approach to therapy of ovarian cancer</strong></td>
</tr>
<tr>
<td>Gordon Mills</td>
<td>UTMD Anderson Cancer Center, USA</td>
</tr>
<tr>
<td><strong>6:15pm</strong></td>
<td><strong>The importance of reproducible research in high-throughput biology: case studies in forensic bioinformatics</strong></td>
</tr>
<tr>
<td>Keith Baggerly</td>
<td>UTMD Anderson Cancer Center, USA</td>
</tr>
<tr>
<td><strong>6:50pm</strong></td>
<td><strong>Review Session</strong></td>
</tr>
<tr>
<td><strong>7:50pm</strong></td>
<td><strong>Close</strong></td>
</tr>
<tr>
<td><strong>8:00pm</strong></td>
<td><strong>Cocktail Reception</strong></td>
</tr>
<tr>
<td><strong>Ballroom Salon C</strong></td>
<td></td>
</tr>
<tr>
<td><strong>8:30pm</strong></td>
<td><strong>Farewell Dinner &amp; Fellowship Prize Presentation</strong></td>
</tr>
<tr>
<td><strong>Ballroom Salon C</strong></td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Each presentation will be a maximum of 25 minutes in duration with a further 10 minutes for questions and discussion.
Wednesday 19th January
Targeting the Other Half of the Tumour

<table>
<thead>
<tr>
<th>MORNING SESSION</th>
<th>Ballroom Salon A &amp; B</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chair:</strong> Iain McNeish Barts and The London School of Medicine and Dentistry, UK</td>
<td></td>
</tr>
<tr>
<td><strong>8:15am</strong> Introduction Iain McNeish Barts and The London School of Medicine and Dentistry, UK</td>
<td></td>
</tr>
<tr>
<td><strong>8:20am</strong> Bad blood: the role of platelets in ovarian carcinoma Anil Sood UTMD Anderson Cancer Center, USA</td>
<td></td>
</tr>
<tr>
<td><strong>8:55am</strong> Inflammatory cytokines and autocrine tumour-promoting networks in ovarian cancer Frances Balkwill Barts and The London School of Medicine and Dentistry, UK</td>
<td></td>
</tr>
<tr>
<td><strong>9:30am</strong> Unraveling the tumour microenvironment in ovarian cancer reveals multiple origins and functional consequences of stromal participants Frank Marini UTMD Anderson Cancer Center, USA</td>
<td></td>
</tr>
<tr>
<td><strong>10:05am</strong> Break Ballroom Foyer</td>
<td></td>
</tr>
<tr>
<td><strong>10:35am</strong> Ovarian cancer immunotherapy George Coukos University of Pennsylvania, USA</td>
<td></td>
</tr>
<tr>
<td><strong>11:10am</strong> The role of adipocytes in promoting ovarian cancer metastasis Ernst Lengyel University of Chicago Medical Center, USA</td>
<td></td>
</tr>
<tr>
<td><strong>11:45am</strong> Clinical implications of regulators of self renewal in cancer Michael Clarke Institute for Stem Cell Biology and Regenerative Medicine, USA</td>
<td></td>
</tr>
<tr>
<td><strong>12:20pm</strong> Discussion</td>
<td></td>
</tr>
<tr>
<td><strong>1:20pm</strong> Closing remarks</td>
<td></td>
</tr>
<tr>
<td><strong>1:30pm</strong> Lunch Salon C</td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Each presentation will be a maximum of 25 minutes in duration with a further 10 minutes for questions and discussion
2011 Forum Delegates

Dr Ahmed Ashour Ahmed
John Radcliffe Hospital Women’s Centre, Headley Way, Headington, Oxford OX3 9DU, UK
TEL: +44 (0)1865 740382
FAX: +44 (0)1865 769141
EMAIL: ahmed.ahmed@obs-gyn.ox.ac.uk

Professor Keith Baggerly
UTMD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1410, Houston, TX 77030, USA
TEL: +1 713 563 4290
FAX: +1 713 563 4244
EMAIL: kabagg@mdanderson.org

Professor Frances Balkwill
Institute of Cancer, Barts and The London School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
TEL: +44 (0)20 7882 3587
FAX: +44 (0)20 7822 3885
EMAIL: f.balkwill@qmul.ac.uk

Professor Robert C. Bast Jr
Office of Translational Research, UTMD Anderson Cancer Center, 1400 Pressler Street, Unit 1439 Houston, TX 77030, USA
TEL: +1 713 792 7743
FAX: +1 713 792 7864
EMAIL: rbast@mdanderson.org

Professor Andrew Berchuck
Div. of Gynecologic Oncology, Duke University Medical Center, PO Box 3079, Durham, NC 27710, USA
TEL: +1 919 684 4943
FAX: +1 919 684 8719
EMAIL: berch001@mc.duke.edu

Professor Jonathan Berek
Women’s Cancer Center, Dept of Obstetrics and Gynecology, Stanford University School of Medicine, 300 Pasteur Drive, Room HH333, Stanford, CA 94305-5317, USA
TEL: +1 650 723 5533
FAX: +1 650 723 7737
EMAIL: jjberek@stanford.edu

Professor Michael Birrer
Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston MA 02114, USA
TEL: +1 617 643 4730
FAX: +1 617 724 6938
EMAIL: mbirrer@partners.org

Professor Michael Bookman
Arizona Cancer Centre, 1515 N. Campbell Ave, Rm 2942-F, Tucson, AZ 85724-5024, USA
TEL: +1 520 626 3600
EMAIL: mbookman@azcc.arizona.edu

Professor David Bostrell
Ovarian Cancer Study Research, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, VIC 3002, Australia
TEL: +61 3 9656 1356
FAX: +61 3 9656 1414
EMAIL: david.bowtell@petermac.org

Dr James Brenton
Cambridge Research Institute, Cancer Research UK, Li Ka Shing Research Center, Robinson Way, Cambridge CB2 0RE, UK
TEL: +44(0)1223 404430
EMAIL: james.brenton@cancer.org.uk

Professor Robert Brown
Ovarian Cancer Action Research Centre, Imperial College London, Hamnersmith Hospital, Du Cane Road, London, W12 0NN, UK
TEL: +44 (0)20 7594 1804
EMAIL: b.brown@imperial.ac.uk

Dr Jeremy Chien
The Mayo Clinic, Laboratory Medicine and Pathology, 200 First Street SW, Rochester MN 55905, USA
TEL: +1 507 284 4138
EMAIL: chien.jeremy@mayo.edu

Dr Michael Clarke
Institute for Stem Cell Biology and Regenerative Medicine, 265 Campus Drive, G2021A, Stanford, CA 94305 USA
TEL: +1 650 736 9639
FAX: +1 650 736 2961
EMAIL: mclarke@stanford.edu

Dr George Coukos
University of Pennsylvania, 1315 Biomedical Research Building, 421 Curie Boulevard, Philadelphia PA 19104 USA
TEL: +1 215 421 7384
FAX: +1 215 573 5129
EMAIL: gcks@mail.med.upenn.edu

Dr Jermaine Coward
Medical Oncology Specialist Registrar Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
TEL: +44(0)191445 6148
EMAIL: richard.edmondson@ncc.ac.uk
2011 Forum Delegates

Dr Dariush Etemadmoghadam
Peter MacCallum Cancer Centre, St Andrew’s Place, East Melbourne VIC 3002, Australia
TEL: +61 (0)3 9656 1149
EMAIL: dariush.etemadmoghadam@petermac.org

Mr Alan Farthing
148 Harley Street, London W1G 7LG, UK
TEL: +44 (0)20 7487 4394
FAX: +44 (0)20 7487 5019
EMAIL: a.farthing@imperial.ac.uk

Professor Michael Friedlander
The Prince of Wales Cancer Center, Barker Street, Randwick NSW 2031, Australia
TEL: +61 (0)2 9382 2606
FAX: +61 (0)2 9382 2588
EMAIL: michael.friedlander@unsw.edu.au

Professor Hani Gabra
Ovarian Cancer Action Research Centre, Imperial College London, Hammersmith Hospital campus, Du Cane Road, London W12 0NN, UK
TEL: +44 (0)20 8383 5828
FAX: +44 (0)20 8383 5830
EMAIL: h.gabra@imperial.ac.uk

Dr Simon Gayther
Gynaecological Oncology, University College London, Paul O’Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK
TEL: +44 (0)20 3108 2990
FAX: +44 (0)20 8379 9687
EMAIL: s.gayther@ucl.ac.uk

Ms Tina Grant-Brook
Harvard International plc, Harvard House, The Waterfront, Elistree Road, Elistree, Herts WD6 3BS
TEL: +44 (0)20 8238 7650
EMAIL: tina.grant@harvardplc.com

Mr John Harris
Harvard International plc, Harvard House, The Waterfront, Elistree Road, Elistree, Herts WD6 3BS
TEL: +44 (0)20 8238 7650
EMAIL: john.harris@harvardplc.com

Dr David Huntsman
Pathology and Laboratory Medicine, University of British Columbia, Room 3427, 600 West 10th Avenue, Vancouver BC V5Z 4E6, Canada
TEL: +604 877 6000 ext. 2148
FAX: +604 877 6089
EMAIL: dhuntsma@bccancer.bc.ca

Mrs Allyson Kaye
Ovarian Cancer Action, 8-12 Camden High Street London NW1 0JH, UK
TEL: +44 (0)7860 447 444
EMAIL: allyson@ovarian.org.uk

Professor Stanley Kaye
Institute of Cancer Research, Royal Marsden Hospital, Sycamore House, Downs Road, Sutton SM2 5PT, UK
TEL: +44 (0)20 8661 3539
FAX: +44 (0)20 8661 3541
EMAIL: stan.kaye@rmh.nhs.uk

Dr Elise Kohn
Medical Oncology Branch and Affiliates, National Cancer Institute, 10 Center Drive MSC1906, Bethesda MD 20892, USA
TEL: +1 301 402 2726
FAX: +1 301 480 5142
EMAIL: kohnn@mail.nih.gov

Professor Robert Kurman
Department of Pathology, John Hopkins University School of Medicine, 401 N Broadway, Baltimore MD 21231, USA
TEL: +1 410 955 2804
FAX: +1 410 614 1287
EMAIL: rkurman@jhmi.edu

Dr Johnathan Lancaster
Department for Women’s Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa FL 33612, USA
TEL: +1 813 745 4734
FAX: +1 813 745 4801
EMAIL: johnathan.lancaster@moffitt.org

Professor Jonathan Ledermann
University College London, CR-UK & UCL Cancer Trials Centre, 90 Tottenham Court Road, London W1T 4TJ, UK
TEL: +44 (0)20 7679 9898
FAX: +44 (0)20 7679 9899
EMAIL: j.ledermann@ctc.ucl.ac.uk

Dr Ernst Lengyel
University of Chicago Medical Center, 5841 S. Maryland Avenue, MC 2050, Chicago IL 60637, USA
TEL: +1 773 702 6722
FAX: +1 773 834 2298
EMAIL: elengyel@uchicago.edu

Dr Douglas Levine
Memorial Sloan-Kettering Cancer Centre, Gynecology Service/Dep of Surgery, 1275 York Avenue, New York NY 10065, USA
TEL: +1 212 639 7335
FAX: +1 212 717 3789
EMAIL: levine2@mskcc.org

Dr Christopher Lord
The Breakthrough Toby Robins Breast Cancer Research Centre. Institute of Cancer Research, Fulham Road, London SW3 6JB
TEL: +44 (0)20 7153 5332
FAX: +44 (0)20 7153 5340
EMAIL: chris.lord@icr.ac.u
Dr Amelie Lutz
Stanford University School of Medicine, 318 Campus Drive, E150, Stanford CA 94305, USA
TEL: +1 650 721 2862
FAX: +1 650 724 4948
EMAIL: alutz@stanford.edu

Dr Ranjit Manchanda
Gynaecological Cancer Research Centre, Dept Gynaecological Oncology, EGA Institute for Women's Health, First floor, Maple House, 149 Tottenham Court Road, London W1T 7NF, UK
TEL: +44 (0)20 7380 6931
FAX: +44 (0)20 7380 6929
EMAIL: r.manchanda@ucl.ac.uk

Dr Frank Marini
UTMD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 355, Houston TX 77030, USA
TEL: +1 713 794 5644
FAX: +1 713 794 7044
EMAIL: fmarini@mdanderson.org

Mr Peter Mason
Dept. of Gynaecological Oncology, West London Cancer Centre, Hammersmith Hospital, Du Cane Road, London W10, UK
TEL: +44 (0) 20 7788 3840
FAX: +44 (0)20 7782 3884
EMAIL: peter.mason@imperial.nhs.uk

Professor Iain McNeish
Institute of Cancer, St Barts and the London School of Medicine, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK
TEL: +44 (0)20 7788 3840
FAX: +44 (0)20 7782 3884
EMAIL: i.a.mcneish@qmul.ac.uk

Professor Usha Menon
UCL Elizabeth Garrett Institute of Women's Health, Gynaecological Cancer Research Centre, First Floor Maple House, 149 Tottenham Court Road, London W1T 7DN, UK
TEL: +44 (0)20 7380 6912
FAX: +44 (0)20 7380 6929
EMAIL: u.menon@ucl.ac.uk

Professor Gordon Mills
UTMD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 950, Houston, TX 77030, USA
TEL: +1 713 563 4200
FAX: +1 713 563 4235
EMAIL: gmills@mdanderson.org

Professor Kenneth Nephew
Indiana University School of Medicine, 302 Jordan Hall, 1001 E. Third Street, Bloomington IN 47405, USA
TEL: +1 812 855 9445
FAX: +1 812 855 4436
EMAIL: knephew@indiana.edu

Dr Amit Oza
Princess Margaret Hospital, 610 University Avenue, 5-700, Toronto ON M5G 2M9, Canada
TEL: +416 946 2818
FAX: + 416 946 4467
EMAIL: amit.ozah@uhn.on.ca

Mr Peter Reynolds
Ovarian Cancer Action, 8-12 Camden High Street London NW1 0JH, UK
TEL: +44 (0)20 7380 1730
EMAIL: preynolds@ovarian.org.uk

Dr Michael Seiden
Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia PA 19111, USA
TEL: +1 215 728 3636
FAX: +1 215 728 2571
EMAIL: michael.seiden@fccc.edu

Professor Anil Sood
UTMD Anderson Cancer Center, Unit 1362, P.O. Box 301439, Houston TX 77030, USA
TEL: +1 713 745 5266
FAX: +1 713 792 3643
EMAIL: asood@mdanderson.org

Dr Euan Stronach
Ovarian Cancer Action Research Centre, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
TEL: +44 (0)20 7594 1548
EMAIL: e.stronach@imperial.ac.uk

Dr David Tan
The Royal Marsden Hospital NHS Foundation Trust, Fulham Road, London SW3 6JJ, UK
TEL: +44 (0)7979 520139
EMAIL: david.tan@icr.ac.uk

Dr Sebastian Vaughan
Ovarian Cancer Action Research Centre, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN
EMAIL: p.vaughan@imperial.ac.uk

Professor Henning Walczak
Division of Immunology and Inflammation, Imperial College London, Hammersmith Hospital, 10th floor Commonwealth Bldg., Du Cane Road, London W12 0NN, UK
TEL: +44 (0)20 8383 2094
FAX: +44 (0)20 8383 2788
EMAIL: h.walczak@imperial.ac.uk

Dr Kimberly Wiegand
British Columbia Cancer Agency, 3427-600 West 10th Avenue, Vancouver BC V5Z 4E6, Canada
TEL: +604 877 6000 ext.3074
FAX: +604 877 6178
EMAIL: kwiegand@cw.bc.ca